Clinical Trial Update: Study of BO-112 With Radiotherapy and Nivolumab for Metastatic Refractory NSCLC [Phase 1, Phase 2]

View source ↗

Summary

A clinical trial investigating BO-112 with radiotherapy and nivolumab in metastatic non-small cell lung cancer across Phase 1 and Phase 2 stages.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer Metastatic

Drugs mentioned

• BO-112 (BO-112)
• nivolumab (nivolumab)

Snippet

Sponsor: Clinica Universidad de Navarra, Universidad de Navarra | Conditions: Non-Small Cell Lung Cancer Metastatic | Phase 1, Phase 2 | Status: UNKNOWN